Response to "The need for validation of MI GPSai in patients with CUP: Comment on: "Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type" by J Abraham et al."
Transl Oncol
.
2021 Aug;14(8):101093.
doi: 10.1016/j.tranon.2021.101093.
Authors
Jim Abraham
1
,
Chadi Nabhan
2
,
Matthew Oberley
3
,
Wolfgang Michael Korn
4
,
David Spetzler
5
Affiliations
1
Caris Life Sciences, Phoenix, AZ; Arizona State University, Phoenix, AZ.
2
Caris Life Sciences, Phoenix, AZ; University of South Carolina, Department of Clinical Pharmacy and Outcomes Sciences, Columbia, SC.
3
Caris Life Sciences, Phoenix, AZ.
4
Caris Life Sciences, Phoenix, AZ; University of California in San Francisco, Division of Hematology and Oncology, San Francisco, CA.
5
Caris Life Sciences, Phoenix, AZ; Arizona State University, Phoenix, AZ. Electronic address:
[email protected]
.
PMID:
34167745
PMCID:
PMC8236549
DOI:
10.1016/j.tranon.2021.101093
No abstract available
Publication types
Letter